Increase in cerebral blood flow, reduction in brain fungal burden, and findings on histopathologic examination revealed that the extent of recovery in the VIP@AmB mice was similar to that in the positive control GSH@AMB mice and was better than mice treated with flucytosine, a BBB-penetrating antifungal agent typically used for cryptococcal meningitis; in contrast, the brain tissues of mice in the untreated, AmBisome, and VIP groups were heavily infiltrated with cryptococcus (Fig. 6d, e, Supplementary Fig. S20a, b and Supplementary Fig. S21). The gene discussed is VIP; the disease is Cryptococcal meningitis.